Senti Biosciences’ (SNTI) “Buy” Rating Reaffirmed at Chardan Capital

Senti Biosciences (NASDAQ:SNTI)‘s stock had its “buy” rating reissued by investment analysts at Chardan Capital in a research report issued on Monday,Benzinga reports. They presently have a $10.00 price target on the stock. Chardan Capital’s price objective would suggest a potential downside of 20.51% from the company’s previous close.

Senti Biosciences Price Performance

NASDAQ:SNTI traded up $10.42 during trading hours on Monday, reaching $12.58. 88,910,875 shares of the company traded hands, compared to its average volume of 573,981. Senti Biosciences has a 1-year low of $1.52 and a 1-year high of $16.94. The stock has a market cap of $57.73 million, a P/E ratio of -0.85 and a beta of 2.74. The firm’s 50-day moving average is $2.23 and its 200-day moving average is $2.59.

Senti Biosciences Company Profile

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.